Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis
Martyna WłodarczykAgata Wieczorkiewicz-KabutKrzysztof BiałasAnna KoclęgaIzabela NosterPatrycja ZielińskaGrzegorz HelbigPublished in: Turkish journal of haematology : official journal of Turkish Society of Haematology (2024)
LMV prophylaxis was effective in preventing CMV reactivation with a favorable safety profile. CMV reactivation occurred mostly after LMV discontinuation; thus, extending the duration of prophylaxis beyond 100 days could be beneficial.